Last reviewed · How we verify
Atripla (r)
Atripla is a fixed-dose combination of three antiretroviral drugs that work together to inhibit HIV replication by blocking reverse transcriptase and integrase enzymes.
Atripla is a fixed-dose combination of three antiretroviral drugs that work together to inhibit HIV replication by blocking reverse transcriptase and integrase enzymes. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy.
At a glance
| Generic name | Atripla (r) |
|---|---|
| Sponsor | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Drug class | Antiretroviral combination (NNRTI + NRTI + NtRTI) |
| Target | HIV reverse transcriptase, HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Atripla contains efavirenz (a non-nucleoside reverse transcriptase inhibitor), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor). These three agents target different stages of HIV replication: efavirenz and emtricitabine inhibit reverse transcriptase directly, while tenofovir also inhibits reverse transcriptase and has activity against hepatitis B. The combination provides potent suppression of viral replication when used as part of antiretroviral therapy.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- HIV-1 infection as part of combination antiretroviral therapy
Common side effects
- Dizziness
- Nausea
- Headache
- Rash
- Abnormal dreams
- Fatigue
- Diarrhea
Key clinical trials
- REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment (PHASE4)
- Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS (PHASE3)
- Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients (PHASE2)
- Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects (PHASE4)
- Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir (PHASE4)
- Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence (NA)
- Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population
- Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atripla (r) CI brief — competitive landscape report
- Atripla (r) updates RSS · CI watch RSS
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections portfolio CI